ArticleOphthalmology and therapy2025

One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study.

Zubeyir Yozgat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.